Annual CFO
-$44.85 M
-$1.42 M-3.27%
31 December 2023
Summary:
Galera Therapeutics annual cash flow from operations is currently -$44.85 million, with the most recent change of -$1.42 million (-3.27%) on 31 December 2023. During the last 3 years, it has risen by +$14.69 million (+24.67%). GRTX annual CFO is now -102.33% below its all-time high of -$22.17 million, reached on 31 December 2018.GRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$2.72 M
+$2.07 M+43.29%
30 June 2024
Summary:
Galera Therapeutics quarterly cash flow from operations is currently -$2.72 million, with the most recent change of +$2.07 million (+43.29%) on 30 June 2024. Over the past year, it has increased by +$9.80 million (+78.30%). GRTX quarterly CFO is now at all-time high.GRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$29.94 M
+$8.03 M+21.14%
30 June 2024
Summary:
Galera Therapeutics TTM cash flow from operations is currently -$29.94 million, with the most recent change of +$8.03 million (+21.14%) on 30 June 2024. Over the past year, it has increased by +$18.93 million (+38.74%). GRTX TTM CFO is now -235.36% below its all-time high of -$8.93 million, reached on 31 March 2019.GRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GRTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.3% | +78.3% | +38.7% |
| 3 y3 years | +24.7% | +85.2% | +55.3% |
| 5 y5 years | -102.3% | +78.9% | +4.6% |
GRTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3.3% | +34.0% | at high | +85.2% | at high | +55.9% |
| 5 y | 5 years | -102.3% | +34.0% | at high | +85.2% | at high | +55.9% |
| alltime | all time | -102.3% | +34.0% | at high | +85.2% | -235.4% | +55.9% |
Galera Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$2.72 M(-43.3%) | -$29.94 M(-21.1%) |
| Mar 2024 | - | -$4.79 M(-51.7%) | -$37.97 M(-15.3%) |
| Dec 2023 | -$44.85 M(+3.3%) | -$9.91 M(-20.8%) | -$44.85 M(-8.2%) |
| Sept 2023 | - | -$12.52 M(+16.5%) | -$48.88 M(+7.3%) |
| June 2023 | - | -$10.75 M(-7.9%) | -$45.57 M(+4.3%) |
| Mar 2023 | - | -$11.67 M(-16.3%) | -$43.71 M(+0.6%) |
| Dec 2022 | -$43.43 M(-36.1%) | -$13.95 M(+51.4%) | -$43.43 M(-7.5%) |
| Sept 2022 | - | -$9.21 M(+3.6%) | -$46.93 M(-16.4%) |
| June 2022 | - | -$8.89 M(-21.9%) | -$56.12 M(-12.4%) |
| Mar 2022 | - | -$11.38 M(-34.7%) | -$64.04 M(-5.8%) |
| Dec 2021 | -$67.96 M | -$17.45 M(-5.2%) | -$67.96 M(+1.5%) |
| Sept 2021 | - | -$18.40 M(+9.5%) | -$66.96 M(+4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$16.80 M(+9.8%) | -$63.84 M(+2.2%) |
| Mar 2021 | - | -$15.30 M(-7.0%) | -$62.45 M(+4.9%) |
| Dec 2020 | -$59.54 M(+27.6%) | -$16.45 M(+7.6%) | -$59.54 M(+2.0%) |
| Sept 2020 | - | -$15.28 M(-0.8%) | -$58.36 M(+4.3%) |
| June 2020 | - | -$15.41 M(+24.4%) | -$55.98 M(+11.7%) |
| Mar 2020 | - | -$12.39 M(-18.9%) | -$50.12 M(+7.4%) |
| Dec 2019 | -$46.66 M(+110.5%) | -$15.28 M(+18.4%) | -$46.66 M(+48.7%) |
| Sept 2019 | - | -$12.90 M(+35.0%) | -$31.39 M(+69.8%) |
| June 2019 | - | -$9.55 M(+7.0%) | -$18.48 M(+107.0%) |
| Mar 2019 | - | -$8.93 M | -$8.93 M |
| Dec 2018 | -$22.17 M(-5.3%) | - | - |
| Dec 2017 | -$23.41 M | - | - |
FAQ
- What is Galera Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Galera Therapeutics?
- What is Galera Therapeutics annual CFO year-on-year change?
- What is Galera Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Galera Therapeutics?
- What is Galera Therapeutics quarterly CFO year-on-year change?
- What is Galera Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Galera Therapeutics?
- What is Galera Therapeutics TTM CFO year-on-year change?
What is Galera Therapeutics annual cash flow from operations?
The current annual CFO of GRTX is -$44.85 M
What is the all time high annual CFO for Galera Therapeutics?
Galera Therapeutics all-time high annual cash flow from operations is -$22.17 M
What is Galera Therapeutics annual CFO year-on-year change?
Over the past year, GRTX annual cash flow from operations has changed by -$1.42 M (-3.27%)
What is Galera Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GRTX is -$2.72 M
What is the all time high quarterly CFO for Galera Therapeutics?
Galera Therapeutics all-time high quarterly cash flow from operations is -$2.72 M
What is Galera Therapeutics quarterly CFO year-on-year change?
Over the past year, GRTX quarterly cash flow from operations has changed by +$9.80 M (+78.30%)
What is Galera Therapeutics TTM cash flow from operations?
The current TTM CFO of GRTX is -$29.94 M
What is the all time high TTM CFO for Galera Therapeutics?
Galera Therapeutics all-time high TTM cash flow from operations is -$8.93 M
What is Galera Therapeutics TTM CFO year-on-year change?
Over the past year, GRTX TTM cash flow from operations has changed by +$18.93 M (+38.74%)